Fujifilm to Develop AI-Based Technology for Analysis of Coronavirus-Induced Pneumonia
By HospiMedica International staff writers Posted on 23 May 2020 |
Image: CT images of a patient who has developed pneumonia as a complication of COVID-19 and analysis results (Photo courtesy of Fujifilm Corporation)
Fujifilm Corporation (Tokyo, Japan) will begin a research study to develop Artificial Intelligence (AI)-based technology to aid in the diagnosis and treatment assessment of patients with COVID-19-induced pneumonia.
Fujifilm has been working on developing AI technology that can be used for assisting medical diagnostic imaging, facilitating workflow at the medical frontline and delivering maintenance services for medical equipment. Fujifilm will apply the CT quantification technology for interstitial pneumonia to develop the technology that helps evaluate the progress of patients with COVID-19-induced pneumonia and determine the effectiveness of treatments.
Fujifilm's CT quantification technology for interstitial pneumonia is powered by an AI-based software that examines CT images to identify bronchi, blood vessels and normal lungs in lung field as well as seven types of lesions such as reticular opacities, ground-glass opacities and honeycomb lungs, and automatically carries out categorization and measurement to quantify lesions of interstitial pneumonia. It also divides the lung field into 12 zones and shows the volume and ratio of lesions for each of the zones so that clinicians can examine the distribution and progression of lesions within the lung field in details. In addition, the technology is expected to contribute to accelerating the development and evaluation of drug candidates for treating pneumonia induced by COVID-19.
Fujifilm has been working on developing AI technology that can be used for assisting medical diagnostic imaging, facilitating workflow at the medical frontline and delivering maintenance services for medical equipment. Fujifilm will apply the CT quantification technology for interstitial pneumonia to develop the technology that helps evaluate the progress of patients with COVID-19-induced pneumonia and determine the effectiveness of treatments.
Fujifilm's CT quantification technology for interstitial pneumonia is powered by an AI-based software that examines CT images to identify bronchi, blood vessels and normal lungs in lung field as well as seven types of lesions such as reticular opacities, ground-glass opacities and honeycomb lungs, and automatically carries out categorization and measurement to quantify lesions of interstitial pneumonia. It also divides the lung field into 12 zones and shows the volume and ratio of lesions for each of the zones so that clinicians can examine the distribution and progression of lesions within the lung field in details. In addition, the technology is expected to contribute to accelerating the development and evaluation of drug candidates for treating pneumonia induced by COVID-19.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans